C83.49 Immunoblastic (diffuse) non-Hodgkin's lymphoma, extranodal and solid organ sites

Name of the Condition

• Immunoblastic (diffuse) non-Hodgkin's lymphoma, extranodal and solid organ sites
• Also known as ICD-10 code C83.49

Summary

Immunoblastic (diffuse) non-Hodgkin's lymphoma is a subtype of non-Hodgkin lymphoma characterized by the malignant proliferation of immunoblasts, a type of immature B-cell. It typically involves diffuse growth patterns in lymph nodes or other lymphoid tissues, with a tendency for rapid progression. This condition is part of the broader category of non-follicular lymphomas and may present with variable clinical behavior depending on the specific subtype.

Causes

The exact cause of immunoblastic (diffuse) non-Hodgkin's lymphoma remains unknown. It is thought to involve genetic mutations or abnormalities in B-cell development, though specific triggers are not well-defined. Research suggests potential links to immune system dysregulation or prior infections, but no definitive etiology has been established.

Risk Factors

• Age: More common in older adults.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Swollen, painless lymph nodes.
• Unexplained weight loss.
• Fever.
• Night sweats.
• Fatigue.
• Loss of appetite.

Diagnosis

Diagnosis involves a combination of physical examination, imaging studies (e.g., CT or MRI), and biopsy of affected tissue. Laboratory tests, including blood work and immunophenotyping, may help confirm the subtype and assess disease extent. Staging is performed to determine the spread of the lymphoma.

Treatment Options

Treatment depends on the stage, location, and patient health. Options include chemotherapy, immunotherapy, radiation therapy, or targeted therapies. Stem cell transplantation may be considered for advanced cases. Treatment plans are individualized based on clinical factors.

Prognosis and Follow-Up

Prognosis varies based on disease stage, subtype, and patient response to treatment. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression. Long-term surveillance may be recommended.

Complications

Potential complications include infection due to immunosuppression, organ dysfunction from tumor burden, or treatment-related side effects (e.g., cytopenias, organ toxicity). Rarely, transformation to a more aggressive lymphoma may occur.

Lifestyle & Prevention

Maintaining a healthy immune system through balanced nutrition, regular exercise, and avoiding known carcinogens (e.g., tobacco) may support overall health. Managing chronic infections or immunosuppressive conditions under medical guidance is advised.

When to Seek Professional Help

Seek medical attention for persistent symptoms like unexplained weight loss, fever, or swollen lymph nodes. Prompt evaluation is critical if symptoms worsen or new concerning signs (e.g., severe fatigue, bleeding) develop.

Tips for Medical Coders

Code C83.49 is used for immunoblastic (diffuse) non-Hodgkin's lymphoma involving extranodal and solid organ sites. Documentation should specify the site(s) of involvement to support accurate coding. Ensure alignment with ICD-10-CM guidelines for lymphoma coding and site-specific documentation requirements.